As such, the anti-vascular endothelial growth factor monoclonal antibody bevacizumab, used for the treatment of VS, may have dual functionality by reducing angiogenesis in NF2-SWN patients and therefore supressing tumour-associated macrophage infiltration, modifying the immunosuppressive microenvironment and reducing tumour growth in the perivascular regions determined in this study.13 The gene discussed is NF2; the disease is neoplasm.